CA
NZ
UK
AU
IND
US
Exelixis (Nasdaq:EXEL) closed at $53.03 at last closing, down $2.94 or 5.25%, on roughly 3.0 million shares against a recent daily average nearer two million. The size of the fall matches the move flagged in early commentary. Its cause does not match the usual …
GE HealthCare (Nasdaq:GEHC) shares closed at $68.02 at last closing, down 2.75% on the day and 5.4% below the $71.90 close reached on 29 July, when second-quarter results lifted the stock 12.15% on volume of 15.3 million shares, several times its recent daily average. …
The second-quarter report Edwards Lifesciences (NYSE:EW) filed at last closing was, on its face, the cleanest print the structural heart company has produced in some time. Sales of $1.74 billion rose 13.6% as reported and 12.5% in constant currency against $1.53 billion a year …
Biogen (Nasdaq:BIIB)'s investment case has rested on one question since Tecfidera lost exclusivity: could new medicines grow faster than old ones decay? On 29 July the company reported that the crossover had arrived. Its growth portfolio delivered $1.06 billion of second-quarterRevenue, up 24% year …
BioMarin (Nasdaq:BMRN) closed its all-cash acquisition of Amicus Therapeutics at last closing at $14.50 a share, about $4.8bn of equity value and $5.32bn of total consideration once equity awards, transaction expenses and repaid Amicus debt are counted. It brings in Galafold for Fabry disease …
BioNTech (Nasdaq:BNTX) closed at $90.58, down 2.44% on the session and about 18% over the past twelve months. The German biotech that co-developed Comirnaty with Pfizer now books so littleVaccineincome that its quarterly revenue is smaller than the quarterly cost of its research organization. …
Boston Scientific (NYSE:BSX) delivered better numbers than it had promised for the June quarter and lowered its full-year outlook in the same release. Net sales of $5.442 billion on 29 July rose 7.5% as reported and 7.0% organically. AdjustedEarningsof $0.86 a share topped the …
BridgeBio Pharma (Nasdaq:BBIO) shares closed at $80.09, down $2.05, or 2.50%, on volume of roughly 2.13 million shares. The dip is noise against the trend: the stock has gained about 76% over 12 months, sits inside a 52-week range of $42.09 to $93.42, and …
Bristol Myers Squibb (NYSE:BMY) lifted its 2026 outlook sharply on 30 July. Full-year revenue guidance moved to $49.0–$50.0 billion from the $46.0–$47.5 billion set in April, and non-GAAPEarnings Per Shareto $6.75–$7.00 from $6.05–$6.35. Second-quarter revenue reached $13.0 billion, up 6% as reported and 5% …
Corcept Therapeutics (Nasdaq:CORT) shares slipped 2.7% on Friday 31 July, closing at $115.17. That decline says far less about theBusinessthan the session before it. On 30 July, the day after second-quarter results landed, the stock climbed 27.3% on 4.5 million shares, roughly four times …
Please wait processing your request...